Fah Bouaré Mehdi Laghmari Felicité Nyafame Etouche Badr Arjdal Imane Saidi Farouk Hajhouji Houssine Ghannane Lamyae Amro Noura Tassi Said Ait Benali
10.11604/pamj.supp.2020.35.2.24952
Pan Afr Med J
2020 Jul 13;35(Suppl 2):110.
covid-19 coronavirus hiv sars-ncov-2 anti-tubercular agents rifampin tuberculosis
CC BY
https://pubmed.ncbi.nlm.nih.gov/33282065/
COVID-19 / diagnosis HIV Infections / diagnosis HIV-1 SARS-CoV-2 Tuberculosis, Pulmonary / diagnosis
COVID-19 / diagnosis HIV Infections / diagnosis HIV-1 SARS-CoV-2 Tuberculosis, Pulmonary / diagnosis Case Reports Adult Antimalarials / administration & dosage Antimalarials / therapeutic use Antiviral Agents / administration & dosage Antiviral Agents / therapeutic use COVID-19 / complications COVID-19 Drug Treatment Chloroquine / administration & dosage Chloroquine / therapeutic use Diagnosis, Differential Drug Therapy, Combination Female HIV Infections / complications HIV Infections / drug therapy Humans Rifampin / administration & dosage Rifampin / therapeutic use Tomography, X-Ray Computed Tuberculosis, Pulmonary / complications Tuberculosis, Pulmonary / diagnostic imaging Tuberculosis, Pulmonary / drug therapy Antimalarials Antiviral Agents Chloroquine Rifampin
PMC7687509
33282065
Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin
2020